Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Four countries to boycott Eurovision 2026 over Israel’s inclusion - 2France will build a new aircraft carrier as it increases defense spending
- 312 Once-In-A-Lifetime Travel Experiences To Add to Your Bucket List
- 4Former 'Bachelorette' welcomes 1st baby via emergency c-section
- 5Share your pick for the tree that you love for its novel magnificence!
- Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes
- Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- Family-Accommodating Snow Sports Experiences
- Skeleton of famed musketeer possibly found in Dutch church
- A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- No more attempts to free whale stranded off Germany, officials say
- Finding the Universe of Workmanship: Individual Encounters in Imagination
- Vote In favor of Your #1 Electric Vehicles
- Emotional wellness Matters: My Fight with Tension
